Document:

Form of Registration Rights Agreement

 Exhibit 4.1 
 EXECUTION COPY 
 REGISTRATION RIGHTS AGREEMENT

 This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January     ,
2010, is made and entered into by and among Solta Medical, Inc., a Delaware corporation (the “Company”), and the purchasers of the Company’s common stock, par value $0.001 per share (the “Common Stock”), who or
that are signatories hereto (collectively, the “Investors”) in connection with the private placement by the Company of the Common Stock. 
 A. The Company has entered into a Securities Purchase Agreement with the Investors dated on or about January 7, 2010 (the “Purchase Agreement”), pursuant to which the Investors
purchased an aggregate 8,529,704 shares of Common Stock and warrants to purchase up to an aggregate of 4,264,852 shares of Common Stock. 
 B. Pursuant to the terms of the Purchase Agreement, the Company has agreed to provide the Holders with certain registration rights with respect to (i) all of the shares of Common Stock purchased
pursuant to the Purchase Agreement, (ii) all of the shares of Common Stock underlying the warrants purchased pursuant to the Purchase Agreement and (iii) any securities issued or issuable upon any stock split, dividend or other
distribution, recapitalization or similar event with respect to the foregoing (collectively, the “Registrable Securities”). Each holder of Registrable Securities is referred to herein as a “Holder” and collectively,
the “Holders.” 
 NOW, THEREFORE, the Company and the Investors hereby covenant and agree as follows:

 ARTICLE 1 
 REGISTRATION RIGHTS AND PROCEDURES 
 1.1 Filing of Registration
Statement. Subject to the terms and conditions of this Agreement, the Company shall prepare a Registration Statement on Form S-3, or other applicable form if Form S-3 is not available or has been rescinded or replaced (the “Initial
Registration Statement”), with respect to the Registrable Securities and shall file the Initial Registration Statement with the Securities and Exchange Commission (the “SEC”) as promptly as possible after the date hereof,
but in any event within thirty (30) days following the Closing Date (as defined in the Purchase Agreement) (the “Filing Deadline”). The Initial Registration Statement, and any other registration statement filed pursuant to this
Agreement, shall include a plan of distribution substantially in the form set forth in Exhibit A (the “Plan of Distribution”), except if otherwise directed by the Investors or required by the SEC. Notwithstanding the registration
obligations set forth in this Section 1.1, if the SEC informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415 under the Securities Act of 1933, as amended (the “Securities
Act”), be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the holders thereof and use its reasonable best efforts to file amendments to the Initial
Registration Statement as required by the SEC and/or (ii) withdraw the Initial Registration Statement and file a new registration statement (a “New Registration Statement”), in either case covering the maximum number of
Registrable Securities permitted to be registered by the SEC, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering; provided, however, that prior to filing such amendment or
New Registration Statement, the Company shall be obligated to use reasonable best efforts to advocate with the SEC for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, the
Manual of Publicly Available Telephone Interpretations D.29. Notwithstanding any other provision of this Agreement to the contrary, if any written or oral guidance, comments, requirements or requests of the SEC staff (“SEC
Guidance”) sets forth a limitation of the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate
with the SEC for the registration of all or a greater number of Registrable Securities), unless

 
otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced with respect to
each Holder on a pro rata basis based on the total number of unregistered Registrable Securities held by such Holders, subject to a determination by the SEC that certain Holders must be reduced first based on the number of Registrable Securities
held by such Holders). In the event the Company amends the Initial Registration Statement or files a New Registration Statement, as the case may be, under clauses (i) or (ii) above, the Company will use reasonable best efforts to file with
the SEC, as promptly as allowed by the SEC or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable
Securities that were not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement (the “Additional Registration Statements”). For purposes of this Agreement, the Filing Deadline of
an Additional Registration Statement shall be the fifth (5th) trading day after the date that the Company is allowed to file such Additional Registration Statement by the SEC or SEC Guidance provided to the Company and the Initial Registration Statement, any New Registration Statement and any
Additional Registration Statement may be referred to as a “Registration Statement.” 
 1.2 Effectiveness of
Registration Statement. 
 (a) The Company shall use reasonable best efforts to have the Initial
Registration Statement or the New Registration Statement, as the case may be, declared effective by the SEC within ninety (90) days following the Closing Date (the “Effectiveness Deadline”); provided, that if the Company
is notified by the SEC that the Initial Registration Statement or the New Registration Statement, as the case may be, will not be reviewed or is no longer subject to review or comment, the Effectiveness Deadline shall be the fifth (5th) trading day following the date that the Company was so
notified; provided, further, that if any Effectiveness Deadline falls on a Saturday, Sunday or other day that the SEC is closed for business, such Effectiveness Deadline shall be extended to the next Business Day on which the SEC is
open for business. Notwithstanding the foregoing and except as otherwise provided in this Agreement, the Effectiveness Deadline of any Additional Registration Statement shall be the earlier of (i) the fifth (5th) trading day following the date that the Company is notified by
the SEC that the Additional Registration Statement will not be reviewed or is no longer subject to review or comment and (ii) ninety (90) days following the Filing Deadline of such Additional Registration Statement. 
 (b) The Company shall use reasonable best efforts, subject to Section 1.2(d) hereof, to prepare and file with the SEC such
amendments and supplements to the Initial Registration Statement, the New Registration Statement and each Additional Registration Statement, as applicable, and each prospectus included in any such Registration Statement, as amended or supplemented
from time to time (a “Prospectus”) used in connection therewith as may be necessary to keep each such Registration Statement effective with respect to any Registrable Securities, until the earlier of (i) the date on which all
of the Registrable Securities covered by the Registration Statements have been sold by the Holders pursuant to a Registration Statement filed pursuant to this Agreement, (ii) the date on which either all of the Registrable Securities are
distributed or saleable to the public without volume or manner of sale limitations pursuant to Rule 144 promulgated by the SEC under the Securities Act (or any similar provision then in effect, “Rule 144”), (iii) the second
anniversary of the Closing Date (provided, however, that such two-year period will be extended for a period of time equal to the period any Investor is required to suspend sales of such Registrable Securities pursuant to the terms of
this Agreement), or (iv) the date on which all of the outstanding Registrable Securities are sold to the Company (but not before the expiration of the applicable prospectus delivery requirements) (the “Effectiveness Period”).

 (c) The Company shall use reasonable best efforts to comply with the provisions of the Securities Act with respect to the
disposition of all securities covered by the Registration Statement during the Effectiveness Period in accordance with the intended methods of disposition by the sellers thereof set forth in the Registration Statement. 
  

 2 

 (d) Notwithstanding anything in this Agreement to the contrary, after 60 consecutive trading
days of continuous effectiveness of any Registration Statement filed and declared effective pursuant to this Agreement, the Company may, by written notice to the Holders, suspend sales under such Registration Statement after the effective date
thereof and/or require that the Holders immediately cease the sale of shares of Common Stock pursuant thereto and/or defer the filing of any subsequent Registration Statement if the Company is engaged in a material merger, acquisition or sale and
the Company’s Board of Directors determines in good faith, by appropriate resolutions, that, as a result of such activity, (A) it would be materially detrimental to the Company (other than as relating solely to the price of the Common
Stock) to maintain the Registration Statement at such time or (B) it is in the best interests of the Company to suspend sales under such registration at such time. Upon receipt of such notice, each Holder shall immediately discontinue any sales
of Registrable Securities pursuant to such registration until such Holder is advised in writing by the Company that the current Prospectus included in the Registration Statement, as applicable, may be used. In no event, however, shall this right be
exercised to suspend sales beyond the period during which (in the good faith determination of the Company’s Board of Directors) the failure to require such suspension would be materially detrimental to the Company. The Company’s rights
under this Section 1.2(d) may be exercised for a period of no more than 20 trading days at a time and not more than three times in any twelve-month period, without such suspension being considered as part of an Event (as defined below)
determination. Immediately after the end of any suspension period under this Section 1.2(d), the Company shall take all necessary actions (including filing any required supplemental prospectus) to restore the effectiveness of the
applicable Registration Statement and the ability of the Holders to publicly resell their Registrable Securities pursuant to such effective Registration Statement. 
 1.3 Notification of Effectiveness. The Company shall promptly notify the Holders via facsimile or electronic mail of a “.pdf” format data file of the effectiveness of the Registration
Statement on the same trading day that the Company telephonically confirms effectiveness with the SEC, which date of confirmation shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 A.M. New York
City time on the first trading day after the Effective Date, file a final Prospectus with the SEC, as required by Rule 424(b) under the Securities Act. Failure to so notify the Holders on or before the second trading day after such notification or
effectiveness or failure to file a final prospectus as aforesaid shall be deemed an Event under Section 1.4. 
 1.4
Events. If: (i) any Registration Statement is not filed with the SEC on or prior to its applicable Filing Deadline, (ii) any Registration Statement is not declared effective by the SEC (or otherwise does not become effective) for
any reason on or prior to its applicable Effectiveness Deadline or (iii) after any Registration Statement is declared effective, (A) the Registration Statement ceases for any reason (including without limitation by reason of a stop order,
or the Company’s failure to update the Registration Statement), to remain continuously effective as to all Registrable Securities included in the Registration Statement or (B) the Holders are not permitted to utilize the Prospectus to
resell such Registrable Securities for any reason for more than an aggregate of twenty (20) consecutive calendar days or forty (40) calendar days (which need not be consecutive days) during any twelve (12) month period, or
(iv) the Company fails to satisfy the current public information requirement pursuant to Rule 144(c)(1) as a result of which the Holders who are not affiliates are unable to sell Registrable Securities without restriction under Rule 144 (or any
successor thereto), (any such failure or breach in clauses (i) through (iv) above being referred to as an “Event,” and, for purposes of clauses (i), (ii) or (iv), the date on which such Event occurs, or for purposes
of clause (iii), the date on which such twenty (20) or forty (40) calendar day period is exceeded, being referred to as an “Event Date”), then in addition to any other rights the Holders may have hereunder or under
applicable law, (x) on each Event Date the Company shall pay to each Holder an amount in cash, as partial liquidated damages and

  

 3 

 
not as a penalty, equal to 1% of the aggregate purchase price paid under the Purchase Agreement for the Registrable Securities then held and registered under the applicable Registration
Statement; and (y) on each monthly anniversary of each such Event Date thereof (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as
partial liquidated damages and not as a penalty, equal to 1% of the aggregate purchase price paid under the Purchase Agreement for the Registrable Securities then held and registered under the applicable Registration Statement. It shall be a
condition precedent to the obligations of the Company to pay any liquidated damages pursuant to this Section 1.4 with respect to the Registrable Securities of any Holder that such Holder shall furnish to the Company such information
regarding itself and the Registrable Securities held by it. The partial liquidated damages pursuant to the terms hereof shall apply on a pro rata basis for any portion of a month prior to the cure of an Event. Notwithstanding the foregoing, the
maximum payment to any Holder associated with all Events in the aggregate shall not exceed (i) in any 30-day period following an Event Date, an aggregate of 1% of the aggregate purchase price paid under the Purchase Agreement for the
Registrable Securities then held and registered under a Registration Statement and (ii) 10% of the aggregate purchase price paid under the Purchase Agreement for the Registrable Securities then held and registered under a Registration
Statement. 
 1.5 Registration Procedures. In connection with the Company’s registration obligations hereunder, the
Company shall:
 (a) Not less than four (4) trading days prior to the filing of any Registration Statement filed pursuant
to this Agreement or any related Prospectus or any amendment or supplement thereto, the Company shall furnish to the Holders copies of all such documents proposed to be filed (other than those incorporated by reference). Notwithstanding the
foregoing, the Company shall not be required to furnish to the Holders any prospectus supplement being prepared and filed solely to name new or additional selling securityholders unless such Holders are named in such prospectus supplement. The
Company shall duly consider any comments made by Holders and received by the Company not later than three (3) trading days after the Holders have been furnished with the aforesaid documents, but shall not be required to accept any such comments
to which it reasonably objects. 
 (b) Prepare and file with the SEC such amendments, including post-effective amendments, to
any Registration Statement filed pursuant to this Agreement and any Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for the
Effectiveness Period and prepare and file with the SEC such Additional Registration Statements necessary in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus of any
Registration Statement filed pursuant to this Agreement to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424 under the Securities Act; (iii) respond as promptly
as reasonably possible to any comments received from the SEC with respect to each Registration Statement or any amendment thereto and, as promptly as reasonably possible provide the Holders true and complete copies of all correspondence from and to
the SEC relating to such Registration Statement that pertains to the Holders as selling stockholders named in such Registration Statement but not any comments that would result in the disclosure to the Holders of material and non-public information
concerning the Company; and (iv) comply in all material respects with the provisions of the Securities Act and the Securities Exchange Act of 1934, as amended (“Exchange Act”) with respect to each Registration Statements filed
pursuant to this Agreement and the disposition of all Registrable Securities covered by such Registration Statement. 
 (c)
Notify the Holders as promptly as reasonably possible (and, in the case of (i)(A) below, not less than three (3) trading days prior to such filing) and (if requested by any such Holder) confirm such notice in writing no later than one
(1) trading day following the day: (i)(A) when a Prospectus or any prospectus

  

 4 

 
supplement (but only to the extent notice is required under Section 1.5(a)) or post-effective amendment to any Registration Statement is proposed to be filed; (B) when the SEC notifies
the Company whether there will be a “review” of any Registration Statement and whenever the SEC comments in writing on such Registration Statement (in which case the Company shall provide true and complete copies thereof and all written
responses thereto to each of the Holders that pertain to the Holders as selling stockholders named in such Registration Statement or to the Plan of Distribution, but not information which the Company believes would constitute material and non-public
information); and (C) with respect to each Registration Statement or any post-effective amendment, when the same has been declared effective; (ii) of any request by the SEC or any other Federal or state governmental authority for
amendments or supplements to any Registration Statement or Prospectus or for additional information that pertains to the Holders as selling stockholders named in such Registration Statement or the Plan of Distribution; (iii) of the issuance by
the SEC of any stop order suspending the effectiveness of any Registration Statement filed pursuant to this Agreement covering any or all of the Registrable Securities or the initiation of any action, claim, suit, investigation or proceeding
(“Proceeding”) for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any
jurisdiction, or the initiation or threatening of any Proceeding (including, without limitation, an investigation or partial Proceeding, such as a deposition), whether commenced or threatened for such purpose; (v) of the occurrence of any event
or passage of time that makes the financial statements included or incorporated by reference in any Registration Statement filed pursuant to this Agreement ineligible for inclusion or incorporation by reference therein or any statement made in such
Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other documents so that,
in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading; and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in
the determination of the Company, makes it not in the best interest of the Company to allow continued availability of any Registration Statement filed pursuant to this Agreement or any related Prospectus. 
 (d) Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness
of any Registration Statement filed pursuant to this Agreement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable. 

(e) Furnish to each Holder, without charge, at least one conformed copy of the Initial Registration Statement, any New Registration
Statement or any Additional Registration Statement and each amendment thereto and all exhibits to the extent reasonably requested by such Holder (including those previously furnished or incorporated by reference) promptly after the filing of such
documents with the SEC; provided, that the Company shall have no obligation to provide any document pursuant to this clause that is available on the EDGAR system. 
 (f) Promptly deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Holders may
reasonably request. The Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus
and any amendment or supplement thereto. 
 (g) Prior to any public offering of Registrable Securities, use its reasonable best
efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or

  

 5 

 
exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of those jurisdictions within the United States as any
Holder reasonably requests in writing to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable the disposition in
such jurisdictions of the Registrable Securities covered by any Registration Statement filed pursuant to this Agreement; provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not
then so qualified or subject the Company to any material tax in any such jurisdiction where it is not then so subject. 
 (h)
Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to any Registration Statement filed pursuant to this Agreement, which
certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may request.

 (i) Upon the occurrence of any event contemplated by Section 1.5(c)(v), as promptly as reasonably possible, prepare a
supplement or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to each related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other
required document so that, as thereafter delivered, no any Registration Statement filed pursuant to this Agreement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 1.6
Information. 
 (a) The Company shall make available for inspection by any seller of Registrable Securities, any
underwriter participating in any disposition pursuant any Registration Statement filed pursuant to this Agreement, and any attorney, accountant, or other agent retained by any such seller or underwriter, all financial and other records of the
Company (reasonably requested), the Company’s applicable corporate documents and contracts as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company’s officers, directors,
employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent in connection with any Registration Statement filed pursuant to this Agreement; provided,
however, that each seller of Registrable Securities agrees that information obtained by it as a result of such inspections which the Company has notified the seller in advance that the information is material and nonpublic shall not be used
by it as the basis for any market transaction in the Company’s securities unless and until such information is made generally available to the public and each such seller shall cause any attorney, accountant, or agent retained by such seller or
underwriter to keep confidential any such information. 
 (b) The Company shall cooperate with any registered broker through
which a Holder proposes to resell its Registrable Securities in effecting a filing with the Financial Industry Regulatory Authority, Inc. pursuant to FINRA Rule 5100 as requested by any such Holder and the Company shall pay the filing fee required
for the first such filing within two (2) Business Days of the request therefor. 
 1.7 Rule 144 Information; Maintenance
of Listing Requirements. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit the Holders to sell Registrable Securities to the public without
registration, as long as any Holder owns Registrable Securities, the Company shall (i) timely file all reports required to be filed by the Company after the date hereof pursuant to Section 13(a) or 15(d) of the Exchange Act or, if the
Company is not required to file reports pursuant to Section 13(a) or 15(d) of the Exchange Act, it will prepare and furnish to the

  

 6 

 
Holders and make publicly available the information specified in Rule 144(c)(2) promulgated under the Securities Act, including, without limitation, annual and quarterly financial statements,
together with a discussion and analysis of such financial statements in form and substance substantially similar to those that would otherwise be required to be included in reports required by Section 13(a) or 15(d) of the Exchange Act, as well
as any other information required thereby, in the time period that such filings would have been required to have been made under the Exchange Act, and (ii) furnish to the Holder upon request, as long as such Holder owns any Registrable
Securities, (A) a written statement by the Company, if true, that it has complied with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act, (B) a copy of the Company’s most recent Annual Report on
Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Holder of any rule or regulation of the SEC that permits the sale of any such Registrable Securities without
registration. As long as any Holder owns any Registrable Securities, the Company shall use its reasonable best efforts to maintain the listing of the Company’s Common Stock on the Nasdaq Stock Market. 
 1.8 Expenses. All fees and expenses incident to the Company’s performance of or compliance with its obligations under this
Agreement (excluding any underwriting discounts and selling commissions) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing
sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to be made with any trading market on which the Common Stock is then
listed for trading, (B) with respect to compliance with applicable state securities or Blue Sky laws (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of
the Registrable Securities and determination of the eligibility of the Registrable Securities for investment under the laws of such jurisdictions as requested by the Holders) and (C) with respect to any filing that may be required to be made by
any broker through which a Holder intends to make sales of Registrable Securities with FINRA pursuant to the FINRA Rule 5100, so long as the broker is receiving no more than a customary brokerage commission in connection with such sale),
(ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing Prospectuses if the printing of Prospectuses is reasonably requested by the Holders of a majority of the
Registrable Securities included in any Registration Statement filed pursuant to this Agreement), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability
insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other persons or entities retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the
Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees
performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company
be responsible for any underwriting, broker or similar fees or commissions of any Holder or, except to the extent provided for in the Purchase Agreement, any legal fees or other costs of the Holders. 
 1.9 Underwritten Offering. 
 (a) If the offering is to be underwritten, the Company shall enter into any necessary agreements in connection therewith (including an underwriting agreement containing customary representations,
warranties, and agreements). 
 (b) To the extent any Holders (“Initiating Party”) intend to distribute
Registrable Securities covered by any Registration Statement filed pursuant to this Agreement in an underwritten public offering, all Holders proposing to distribute their securities through such underwriting shall enter into an underwriting

  

 7 

 
agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Agreement, if the underwriter advises an Initiating
Party in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Party shall so advise all holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the
number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Party, in proportion (as nearly as practicable) to the amount of Registrable Securities owned
by each Holder and to be included in the underwriting; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities, if any, including without
limitation securities proposed to be registered and issued by the Company are first entirely excluded from the underwriting. 
 1.10 Nature of Sale. Notwithstanding any other provision of this Agreement, shares of Common Stock shall be treated as Registrable Securities only if and so long as it has not been (a) sold to or through a broker or dealer or
underwriter in a public distribution or a public securities transaction, or (b) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer
restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale. 
 ARTICLE
2 
 RIGHTS AND UNDERTAKINGS OF 
 HOLDERS OF REGISTRABLE SECURITIES 
 2.1 Rights of Holders. Each
holder of Registrable Securities shall have the absolute right to exercise or refrain from exercising any right or rights that such holder may have by reason of this Agreement, including, without limitation, the right to consent to the waiver or
modification of any obligation under this Agreement, and such holder shall not incur any liability to any other holder of any of the Company’s securities as a result of exercising or refraining from exercising any such right or rights.

 2.2 Suspension of Sales; Notice of Sales. If any Registrable Securities are included in a Registration Statement
pursuant to the terms of this Agreement, the holder thereof will not (until further notice) effect sales thereof after receipt of written notice from the Company of the occurrence of an event specified in order to permit the Company to correct or
update the Registration Statement or Prospectus. 
 2.3 Compliance. If any Registrable Securities are being registered in
any registration pursuant to this Agreement, the holder thereof will comply with all anti-stabilization, manipulation, and similar provisions of Section 10 of the Exchange Act and any rules promulgated thereunder by the SEC and, at the
Company’s request, will execute and deliver to the Company and to any underwriter participating in such offering an appropriate agreement to such effect. 
 2.4 Termination of Effectiveness. Following the end of the Effectiveness Period, each holder of Registrable Securities included in the Registration Statement shall discontinue sales thereof
pursuant to the Registration Statement, unless such holder has received written notice from the Company of its intention to continue the effectiveness of any Registration Statement filed pursuant to this Agreement with respect to any of such
securities which remain unsold. 
 2.5 Furnish Information. It shall be a condition precedent to the Company’s
obligations to take any action pursuant to this Agreement with respect to the Registrable Securities of any selling holder that such holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and
the intended method of disposition of such securities as shall be required to effect the registration of such holder’s Registrable Securities or as the Company shall otherwise reasonably request. The obligations of the Company under this
Agreement shall be suspended as to any holder of Registrable Securities unless and until such holder complies with the preceding sentence. 
  

 8 

 2.6 Underwritten Registration. No holder of Registrable Securities may participate in
any registration hereunder which is underwritten unless such holder: (a) agrees to sell such holder’s securities on the basis provided in any underwriting arrangements; (b) completes and executes all customary questionnaires, powers
of attorney, indemnities, underwriting agreements, and other documents reasonably required under the terms of such underwriting arrangements; and (c) agrees to pay its pro rata share of all underwriting discounts and commissions and its
own expenses (including, without limitation, counsel fees). 
 2.7 Delay of Registration. No holder of Registrable
Securities shall have any right to obtain or seek an injunction restraining or otherwise delaying the preparation of, or declaration of the effectiveness of, any Registration Statement initiated in accordance with the terms of this Agreement if such
injunction is the result of any controversy that might arise with respect to the interpretation or implementation of these provisions. 
 ARTICLE 3 
 INDEMNIFICATION 
 3.1 Indemnification by the Company. The Company shall indemnify and hold harmless, with respect to any Registration Statement filed pursuant to this Agreement, to the fullest extent permitted by
law, each Holder of Registrable Securities covered by such Registration Statement, as well as such Holder’s officers, directors, employees, agents, and general or limited partners (and the directors, officers, employees, and agents thereof) and
each other person, if any, who controls such Holder within the meaning of the Securities Act (collectively, the “Holder Indemnified Parties”) against all losses, claims, damages, liabilities, and expenses joint or several (including
reasonable fees of counsel and any amounts paid in settlement effected with the Company’s consent, which consent shall not be unreasonably withheld) (collectively, “Losses”) to which any such Holder Indemnified Party may become
subject under the Securities Act, the Exchange Act, any other federal law, any state or common law, any rule or regulation promulgated thereunder, or otherwise, insofar as such Losses (or Proceedings, whether commenced or threatened, in respect
thereof) are caused by (a) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement in which such Registrable Securities were included as contemplated hereby or the omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (b) any untrue statement or alleged untrue statement of a material fact contained in any preliminary, final, or summary
Prospectus, together with the documents incorporated by reference therein (as amended or supplemented if the Company shall have filed with the SEC any amendment thereof or supplement thereto), or the omission or alleged omission to state therein a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or (c) any violation by the Company of the Securities Act, the
Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities laws in connection with any such registration; provided, however, that the Company shall
not be liable to any Holder Indemnified Party in any such case to the extent that any such Loss (or Proceeding, whether commenced or threatened, in respect thereof) arises out of or is based upon any untrue statement or alleged untrue statement or
omission or alleged omission made in such Registration Statement or amendment thereof or supplement thereto or in any such preliminary, final, or summary Prospectus in reliance upon and in conformity with written information furnished to the Company
by or on behalf of any such Holder Indemnified Party relating to such Holder Indemnified Party for use in the preparation thereof; and provided further, that the Company shall not be liable to any such Holder Indemnified Party with
respect to any preliminary Prospectus to the extent that any such Loss of such Holder Indemnified Party results from the fact that such Holder Indemnified Party sold Registrable Securities to a

  

 9 

 
person to whom there was not timely sent or given a copy of such preliminary Prospectus (excluding documents incorporated by reference) or of the applicable Prospectus as then amended or
supplemented (excluding documents incorporated by reference) if a Prospectus is required to be delivered pursuant to Rule 172 under the Securities Act and the Company previously furnished copies thereof to such Holder Indemnified Party in compliance
with this Agreement and the Loss of such Holder Indemnified Party results from an untrue statement or omission of a material fact contained in such preliminary Prospectus which was corrected in the Prospectus (or the Prospectus as amended or
supplemented). Such indemnity and reimbursement of expenses and obligations shall remain in full force and effect regardless of any investigation made by or on behalf of the Holder Indemnified Parties and shall survive the transfer of such
securities by such Holder Indemnified Parties. The Company shall notify the Holders promptly of the institution, threat, or assertion of any Proceeding of which the Company is aware in connection with any Registration Statement filed pursuant to
this Agreement. 
 3.2 Indemnification by Holders. Each Holder of Registrable Securities registered under any
Registration Statement filed pursuant to this Agreement shall, severally and not jointly, indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors, officers, employees, and agents, and each person who controls
the Company (within the meaning of the Securities Act) (collectively, “Company Indemnified Parties”) against all Losses to which any Company Indemnified Party may become subject under the Securities Act, the Exchange Act, any other
federal law, any state or common law, or otherwise, insofar as such Losses (or Proceedings, whether commenced or threatened, in respect thereof) are caused by (a) any untrue statement or alleged untrue statement of a material fact contained in
any Registration Statement in which such Holder’s Registrable Securities were included or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, (b) any untrue statement or alleged untrue statement of a material fact contained in any preliminary, final, or summary prospectus, together with the documents incorporated by reference therein (as amended or supplemented if the
Company shall have filed with the SEC any amendment thereof or supplement thereto), or the omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading, and in the cases described in clauses (a) and (b) of this Section 3.2, to the extent, but only to the extent, that such untrue statement or omission is contained
in any information furnished in writing by such Holder relating to such Holder for use in the preparation of the documents described in such clauses (a) and (b), (c) any violation by such holder of the Securities Act, the Exchange Act, any
state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities laws, and (d) with respect to any preliminary Prospectus, the fact that such Holder sold Registrable Securities to a
person to whom there was not timely sent or given a copy of the Prospectus (excluding the documents incorporated by reference) or of the Prospectus as then amended or supplemented (excluding documents incorporated by reference) if a Prospectus is
required to be delivered pursuant to Rule 172 under the Securities Act and the Company has previously furnished copies thereof to such Holder in compliance with this Agreement and the Loss of such Company Indemnified Party results from an untrue
statement or omission of a material fact relating to information provided by such Holder contained in such preliminary prospectus which was corrected in the Prospectus (or the Prospectus as amended or supplemented). Such indemnity obligation shall
remain in full force and effect regardless of any investigation made by or on behalf of Company Indemnified Parties and shall survive the transfer of such securities by such Holder. In no event shall the liability of any Holder hereunder be greater
in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation, except in the case of fraud by such Holder. 
 3.3 Conduct of Indemnification Proceedings. Promptly after receipt by an identified party hereunder of written notice of the
commencement of any Proceeding, or threat thereof, with respect to which a claim for indemnification may be made pursuant hereto, such indemnified party shall, if a claim in respect thereto is to be made against an indemnifying party, give written
notice to the indemnifying party of the threat

  

 10 

 
or commencement thereof; provided, however, that the failure to so notify the indemnifying party shall not relieve it from any liability which it may have to any indemnified party
except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. If any such claim or action referred to hereunder is brought against any indemnified party and it then notifies the indemnifying party of the
threat or commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other indemnifying party similarly notified, to assume the defense thereof with counsel reasonably
satisfactory to such indemnified party (which counsel shall not, except with the consent of the indemnified party, be counsel to the indemnifying party). The indemnifying party shall not be liable to an indemnified party hereunder for any legal
expenses of counsel or any other expenses incurred by such indemnified party in connection with the defense thereof, unless the indemnifying party has failed to assume the defense of such claim or action or to employ counsel reasonably satisfactory
to such indemnified party. Notwithstanding the foregoing, the indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The indemnifying party shall not be
required to indemnify the indemnified party with respect to any amounts paid in settlement of any Proceeding entered into without the written consent of the indemnifying party, which consent shall not be unreasonably withheld. No indemnifying party
shall consent to the entry of any judgment or enter into any settlement without the consent of the indemnified party unless (a) such judgment or settlement does not impose any obligation or liability upon the indemnified party other than the
execution, delivery, or approval thereof and (b) such judgment or settlement includes as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a full release and discharge from all liability in
respect of such claim and a full release of all persons that may be entitled to or obligated to provide indemnification or contribution under this Article. 
 3.4 Contribution. If the indemnification provided for herein is unavailable to or insufficient to hold harmless an indemnified party hereunder, then each indemnifying party shall contribute to the
amount paid or payable by such indemnified party as a result of the Losses (or Proceedings in respect thereof) referred to herein in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the
indemnified party on the other in connection with the statements, omissions, actions, or inactions which resulted in such Losses. The relative fault of the indemnifying party and the indemnified party shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or the indemnified party, any action or inaction by any
such party, and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement, omission, action, or inaction. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Promptly after receipt by an indemnified party hereunder of written notice of the commencement of
any Proceeding, or threat thereof, with respect to which a claim for contribution may be made against an indemnifying party hereunder, such indemnified party shall, if a claim for contribution in respect thereto is to be made against an indemnifying
party, give written notice to the indemnifying party of the commencement thereof (if the notice specified herein has not been given with respect to such Proceeding); provided, however, that the failure to so notify the indemnifying
party shall not relieve it from any obligation to provide contribution which it may have to any indemnified party hereunder, except to the extent that the indemnifying party is actually prejudiced by the failure to give notice. The parties hereto
agree that it would not be just and equitable if contribution pursuant hereto were determined by pro rata allocation or by any other method of allocation which does not take account of equitable considerations referred to herein. In no event shall
the liability of any Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation, except in the case of fraud by
such Holder. 
  

 11 

 If indemnification is available hereunder, the indemnifying parties shall indemnify each
indemnified party to the fullest extent provided herein, without regard to the relative fault of said indemnifying party or indemnified party or any other equitable consideration provided for herein. The provisions hereof shall be in addition to any
other rights to indemnification or contribution which any indemnified party may have pursuant to law or contract, shall remain in full force and effect regardless of any investigation made by or on behalf of any indemnified party, and shall survive
the transfer of securities by any such party. 
 ARTICLE 4 
 MISCELLANEOUS 
 4.1 No Piggyback on Registrations;
Prohibition on Filing Other Registration Statements. Neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in a Registration Statement other than the
Registrable Securities, and the Company shall not enter into any agreement that permits other securities of the Company to be registered on any Registration Statement filed pursuant to this Agreement. The Company shall not file with the SEC a
registration statement relating to an offering for its own account under the Securities Act of any of its equity securities other than a registration statement on Form S-8 or, in connection with an acquisition, on Form S-4 until the earlier of
(i) the date that is thirty (30) days after all of the Registrable Securities have been registered on an effective Registration Statement or (ii) the date that all Registrable Securities are eligible for resale by non-affiliates
without volume or manner of sale restrictions under Rule 144 and without the requirement for the Company to be in compliance with the current public information requirements under Rule 144. 
 4.2 Assignment; Successors and Assigns. This Agreement and all provisions thereof shall be binding upon, inure to the benefit of, and
are enforceable by the parties hereto and their respective successors and permitted assigns. An Investor may assign its rights hereunder to any permitted transferee of all or any portion of the Registrable Securities, provided, that
(a) the Company is furnished with written notice of the name and address of the assignee and the securities with respect to which such rights are being assigned and (b) the Company shall have the right to require any holder of Registrable
Securities to execute a counterpart of this Agreement as a condition to such holder’s claim to any rights hereunder. This Agreement may not be assigned by the Company. 
 4.3 Notices. All notices, requests, and other communications hereunder shall be in writing and will be deemed to have been duly given
and received (a) when personally delivered, (b) when sent by facsimile upon confirmation of receipt, (c) one business day after the day on which the same has been delivered prepaid to a nationally recognized courier service, or
(d) five business days after the deposit in the United States mail, registered or certified, return receipt requested, postage prepaid, in each case addressed as follows: 
 (a) if to the Company, then at Solta Medical, Inc., 25881 Industrial Blvd., Hayward, CA 94545, Attn: Chief Executive Officer, facsimile
number: (510) 786-6880, with a copy to Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Rd., Palo Alto, CA 94304, Attn: Chris F. Fennell, Esq., facsimile number: (650) 493-6811; or 
 (b) if addressed to a Holder, then at the address and facsimile number for such Investor set forth in the Purchase Agreement and otherwise
contained in the Company’s books and records. 
 A Holder or the Company may agree in writing to accept notices and other
communications to it hereunder by electronic communications pursuant to procedures reasonably approved by it; provided, that approval of such procedures may be limited to particular notices or communications. Any party hereto from time to
time may change its address, facsimile number, or other information for the purpose of notices to that party by giving notice specifying such change to the other party hereto. 
  

 12 

 4.4 Public Announcements. Except as otherwise required by law, an Investor shall not
issue any press release or make any other public announcement with respect to the transactions contemplated hereby without the approval of the Company, which approval shall not be unreasonably withheld or delayed. 
 4.5 Governing Law; Jurisdiction. 
 (a) This Agreement, and the provisions, rights, obligations, and conditions set forth herein, and the legal relations between the parties hereto, including all disputes and claims, whether arising in
contract, tort, or under statute, shall be governed by and construed in accordance with the laws of the State of California without giving effect to its conflict of law provisions. 
 (b) Any and all disputes arising out of, or in connection with, the interpretation, performance, or nonperformance of this Agreement or any
and all disputes arising out of, or in connection with, transactions in any way related to this Agreement and/or the relationship between the parties shall be litigated solely and exclusively before the United States District Court for the Northern
District of California. The parties consent to the in personam jurisdiction of said court for the purposes of any such litigation, and waive, fully and completely, any right to dismiss and/or transfer any action pursuant to 28 U.S.C. § 1404 or
1406 (or any successor statute). 
 4.6 Third-Party Beneficiaries. Except as set forth in Article 3, this Agreement shall
not confer any rights or remedies upon any person other than the Investors and the other parties hereto and their respective successors and permitted assigns. 
 4.7 Severability. In the event that any provision of this Agreement or the application of any provision hereof is declared to be illegal, invalid, or otherwise unenforceable by a court of competent
jurisdiction, the remainder of this Agreement shall not be affected except to the extent necessary to delete such illegal, invalid, or unenforceable provision unless that provision held invalid shall substantially impair the benefits of the
remaining portions of this Agreement. 
 4.8 Headings. The headings in this Agreement are for convenience of reference
only and shall not constitute a part of this Agreement, nor shall they affect its meaning, construction, or effect. 
 4.9
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original instrument and all of which together shall constitute one and the same instrument. 
 4.10 Entire Agreement. This Agreement embodies the entire understanding and agreement between the parties hereto with respect to the
subject matter hereof and supersedes all prior agreements and understandings relating to the subject matter hereof. 
 4.11
Amendment; Waiver. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to or departures from the provisions hereof may not be given, without the
written consent of the Company and Holders beneficially owning more than fifty percent (50%) of the then outstanding Registrable Securities. Notwithstanding the foregoing, any amendment, modification, supplement, waiver or consent to or
departure from the provisions hereof which (i) affects the rights of a Holder in any manner which is different than that of any other Holder, (ii) adversely affects a Holder’s indemnification rights or obligations hereunder,
(iii) relates to Section 1.7, or

  

 13 

 
(iv) relates to the provisions of this Section 4.11, shall require the prior written consent of each such Holder. In the event that this Agreement is amended without the written consent of
all Holders, then the Company shall deliver a copy of such amendment to all Holders that did not so consent no later than two (2) trading days following the effective date of any such amendment. 
 4.12 Further Assurances. Each party shall cooperate and take such action as may be reasonably requested by another party in order to
carry out the provisions and purposes of this Agreement and the transactions contemplated hereby. 
 [Signature page follows]

  

 14 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed by the undersigned,
thereto duly authorized, as of the date first set forth above. 
  

			
	SOLTA MEDICAL, INC.
		
	By:	 	  

	Name:	 	Stephen J. Fanning
	Title:	 	Chairman, CEO & President

  

 15 

 INVESTORS: 
  

									
		 		 	By:	 	  
	 	(signature)
					
		 		 	Name:	 	  
	 	(printed name)
					
		 		 	Title:	 	Managing Member	 	

							
				
		 	Address:	 	  
	 	
		 	  
	 	
		 	  
	 	
		 	Facsimile No:	 	  
	 	
		 	E-mail Address:	 	  
	 	

 EXHIBIT A 
 PLAN OF DISTRIBUTION 
 The selling stockholders may resell or
redistribute the securities listed elsewhere in this prospectus from time to time on any stock exchange or automated interdealer quotation system on which the securities are listed, in the over-the-counter market, in privately negotiated
transactions, or in any other legal manner, at fixed prices that may be changed, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Persons who are pledgees, donees,
transferees, or other successors in interest of any of the named selling stockholders (including but not limited to persons who receive securities from a named selling stockholder as a gift, partnership distribution or other non-sale-related
transfer after the date of this prospectus) may also use this prospectus and are included when we refer to “selling stockholders” in this prospectus. The selling stockholders may sell the shares being offered from time to time in one or
more transactions: 
  

	 	•	 	 on the Nasdaq Global Market or otherwise; 

  

	 	•	 	 in the over-the-counter market; 

  

	 	•	 	 in negotiated transactions; 

  

	 	•	 	 through broker-dealers, who may act as agents or principals; 

  

	 	•	 	 through one or more underwriters on a firm commitment or best efforts basis; 

  

	 	•	 	 through the writing of options on shares, whether the options are listed on an options exchange or otherwise; 

  

	 	•	 	 a combination of such methods of sale; or 

  

	 	•	 	 any other method permitted pursuant to applicable law. 

 The selling stockholders may also transfer the securities by gift. We do not know of any current arrangements by the selling stockholders for the sale or distribution of any of the securities.

 The selling stockholders also may sell the shares pursuant to Rule 144 adopted under the Securities Act, as permitted by that
rule. The selling stockholders may effect transactions by selling shares directly to purchasers or to or through broker-dealers. The broker-dealers may act as agents or principals. The broker-dealers may receive compensation in the form of
discounts, concessions or commissions from the selling stockholders or the purchasers of the shares. The compensation of any particular broker-dealer may be in excess of customary commissions. Because the selling stockholders and broker-dealers that
participate with the selling stockholders in the distribution of shares may be deemed to be “underwriters” within the meaning of Section 2(11) of the Securities Act, the selling stockholders will be subject to the prospectus delivery
requirements of the Securities Act. Any commissions received by them and any profit on the resale of shares may be deemed to be underwriting compensation. 
 The selling stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their securities.
There is no underwriter or coordinating broker acting in connection with the proposed sale of shares by the selling stockholders. 

 From time to time, one or more of the selling stockholders may pledge, hypothecate or grant
a security interest in some or all of the securities owned by them. The pledgees, secured parties or persons to whom the securities have been hypothecated will, upon foreclosure in the event of default, be deemed to be selling
stockholders. The number of a selling stockholder’s securities offered under this prospectus will decrease as and when it takes such actions. The plan of distribution for that selling stockholder’s securities will otherwise
remain unchanged.
 Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the
shares may not simultaneously engage in market making activities with respect to our common stock for a period of two business days prior to the commencement of such distribution. In addition, each selling stockholder will be subject to applicable
provisions of the Exchange Act and the associated rules and regulations under the Exchange Act, including Regulation M, which provisions may limit the timing of purchases and sales of shares of our common stock by the selling stockholders. We will
make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver copies of this prospectus to purchasers at or prior to the time of any sale of the shares. 
 We will bear all costs, expenses and fees in connection with the registration of the shares. The selling stockholders will bear all
commissions and discounts, if any, attributable to the sales of the shares. The selling stockholders may agree to indemnify any broker-dealer or agent that participates in transactions involving sales of the shares against certain liabilities,
including liabilities arising under the Securities Act. 
 We have agreed to indemnify the selling stockholders and their
respective officers, directors, employees, agents and representatives, and each other person who may be subject to liability because of his, her or its connection with the selling stockholder, against specified liabilities, including liabilities
under the federal securities laws. The selling stockholders have agreed to indemnify us, our officers, directors, employees, agents and representatives and each other person subject to liability because of his, her or its connection with us,
against specified liabilities arising from information provided by the selling stockholder for use in this prospectus, including liabilities under the federal securities laws.
 The securities offered hereby were originally issued to the selling stockholders pursuant to an exemption from the registration requirements
of the Securities Act. We agreed to register the securities under the Securities Act, and to keep the registration statement of which this prospectus is a part effective, as to any selling stockholder, until such time as all of the shares of
common stock held by such selling stockholder registered under the registration statement of which this prospectus is a part can be sold in any one day, without registration, in compliance with Rule 144 of the Securities Act. Other than
underwriting discounts and commissions, if any, we have agreed to bear all reasonable expenses incurred in connection with the registration and sale of the common stock offered by the selling stockholders. 
 Upon notification to us by a selling stockholder that any material arrangement has been entered into with broker-dealers for the sale or
purchase of shares, we will file a supplement to this prospectus, if required, disclosing: 
  

	 	•	 	 the name of the participating broker-dealers, underwriters or agents; 

  

	 	•	 	 the number of shares involved; 

  

	 	•	 	 the price at which such shares were sold; 

  

	 	•	 	 the public offering price; 

	 	•	 	 the commissions paid or discounts or concessions allowed to such broker-dealers, where applicable; 

  

	 	•	 	 the fees or other items constituting compensation to underwriter, agents or broker-dealers with respect to a particular transaction, where applicable;
and 

  

	 	•	 	 other facts material to the transaction.Form of Warrant to purchase common stock

 Exhibit 4.2 
 [FORM OF WARRANT] 
 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A
FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THIS CERTIFICATE AND THE SECURITIES INTO WHICH THESE
SECURITIES ARE EXERCISABLE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. 
 SOLTA MEDICAL, INC. 
 WARRANT TO PURCHASE COMMON STOCK 
 Warrant No.: 
 Number of Shares of Common Stock:

 Date of Issuance: January     , 2010 (“Issuance Date”) 
 Solta Medical, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, [            ], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to
the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer
or replacement hereof, the “Warrant”), at any time or times on or after the date six (6) months after the date hereof (the “Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration
Date (as defined below), [            ] ([            ]) fully paid nonassessable shares of Common Stock (as defined below) (the
“Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 19. This Warrant is one of the Warrants to purchase Common Stock (the
“Warrants”) issued pursuant to Section 2 of the Securities Purchase Agreement (the “Purchase Agreement”), dated as of January 7, 2010, by and among the Company and each Holder. The closing of the
transactions contemplated by the Purchase Agreement occurred on January     , 2010 (the “Closing Date”). 

 1. EXERCISE OF WARRANT. 
 (a) Mechanics of Exercise. Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder on any day on or
after the Exercisability Date, in whole or in part, by delivery of (i) a properly completed and executed written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s
election to exercise this Warrant and (ii) (A) payment to the Company of an amount equal to the applicable Exercise Price (as defined below) multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the
“Aggregate Exercise Price”) in cash or by wire transfer of immediately available funds or (B) by notifying the Company, through delivery of the Exercise Notice, that this Warrant is being exercised pursuant to a Cashless
Exercise. The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as
cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or before the second (2nd) Business Day following the date on which the Company has received each of
the Exercise Notice and the Aggregate Exercise Price (or a duly executed and delivered notice of Cashless Exercise), the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and
American Stock Transfer & Trust Company, the Company’s transfer Agent (“Transfer Agent”). On or before the third (3rd) Business Day following the date on which the Company has received the Exercise Notice (the
“Share Delivery Date”), the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon the request of the
Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or
(Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s
share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Notice and the payment of the Aggregate Exercise Price (or a
duly executed and delivered notice of Cashless Exercise), the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date
such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. If this Warrant is submitted in connection with any exercise pursuant to this
Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event
later than five (5) Business Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 8(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such
exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock
to be issued shall be rounded down to the nearest whole number. The Company shall pay any and all taxes (other than taxes based upon the income of the Holder) which may be payable with respect to the issuance and delivery of Warrant Shares upon
exercise of this Warrant; provided, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the

  

 2 

 
issue and delivery of shares of Common Stock in any name other than that of the Holder, in either case with respect to any income or transfer tax due by the Holder with respect to such shares of
Common Stock issued upon exercise of this Warrant. 
 (b) Exercise Price. For purposes of this Warrant, “Exercise
Price” means $2.121 per share, subject to adjustment as provided herein. 
 (c) Company’s Failure to Timely
Deliver Securities. If the Company shall fail for any reason or for no reason to issue to the Holder within three (3) Business Days of receipt of the Exercise Notice in compliance with the terms of this Section 1, a certificate
for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company’s share register or to credit the Holder’s balance account with DTC for such number of shares of Common Stock
to which the Holder is entitled upon the Holder’s exercise of this Warrant, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the
Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three (3) Business Days after the Holder’s request and in the
Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Bid Price on the date of
exercise. 
 (d) Payment of Exercise Price. The Company shall promptly, and in no case later than the
second (2nd) Business Day immediately following such
receipt, confirm receipt of an Exercise Notice via facsimile to the number specified in such Exercise Notice. The Holder shall pay the Exercise Price to the Company in immediately available funds upon receipt of such confirmation by the Company. The
Holder may, at its election, satisfy its obligation to pay the Exercise Price through a “Cashless Exercise,” in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows: 
  

			
		  	X = Y [(A-B)/A]
		
	where:	  	
		
		  	X = the number of Warrant Shares to be issued to the Holder.
		
		  	Y = the number of Warrant Shares with respect to which this Warrant is being exercised.
		
		  	A = the Weighted Average Price on the Trading Day immediately prior to (but not including) the date on which the Company receives a duly executed and delivered notice of Cashless
Exercise.
		
		  	B = the Exercise Price.

  

 3 

 (e) Rule 144. For purposes of Rule 144(d) promulgated under the Securities
Act, as in effect on the date hereof, it is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the
date this Warrant was originally issued pursuant to the Purchase Agreement. 
 (f) Disputes. In the case of a dispute as
to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed. 
 (g) Beneficial Ownership. The Holder shall not have the right to exercise this Warrant, to the extent that after giving effect to
such exercise, such Person (together with such Person’s affiliates) would beneficially own in excess of 9.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such
exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and
its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or
convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be
calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding
shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more
recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. Except as
set forth in Section 1(h), by written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage; provided, that (i) any such increase will not be effective until the
sixty-first (61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder. 
 (h) Principal Market Regulation. At all times, irrespective of whether the Company is listed on the Principal Market, the Company shall not issue any shares of Common Stock upon exercise of this
Warrant if the issuance of such shares of Common Stock would exceed the aggregate number of shares of Common Stock which the Company may issue upon conversion or exercise or otherwise of all Warrants without breaching the rules or regulations of the
Principal Market as if the Company were regulated by such rules or regulations (the “Exchange Cap”), except that such limitation shall not apply in the event that the Company obtains, at its election, the

  

 4 

 
approval of its stockholders as required by the applicable rules of the Principal Market for issuances of Common Stock in excess of such amount. Until such approval is obtained, no shares of
Common Stock shall be issued in the aggregate, upon conversion or exercise or otherwise, as applicable, of the Warrants, in an amount greater than the product of the Exchange Cap multiplied by a fraction, the numerator of which is the number of
Underlying Shares (as defined in the Purchase Agreement) underlying the Warrants issued to the Holder pursuant to the Purchase Agreement and the denominator of which is the aggregate number of Underlying Shares underlying all of the Warrants issued
pursuant to the Purchase Agreement (with respect to each Holder, the “Exchange Cap Allocation”). In the event that the Holder shall sell or otherwise transfer this Warrant, the transferee, if a registered holder of such Warrant,
shall be allocated a pro rata portion of the Holder’s Exchange Cap Allocation, and the restrictions of the prior sentence shall apply to such transferee with respect to the portion of the Exchange Cap Allocation allocated to such transferee. In
the event that the Holder shall exercise all of the Holder’s Warrants into a number of shares of Common Stock which, in the aggregate, is less than the Holder’s Exchange Cap Allocation, then the difference between the Holder’s
Exchange Cap Allocation and the number of shares of Common Stock actually issued to the Holder shall be allocated to the respective Exchange Cap Allocations of the remaining registered holders of Warrants on a pro rata basis in proportion to the
aggregate number of Warrants then held by each such holder. To the extent required by the Principal Market, the provisions of the Exchange Cap shall be modified to comply with the applicable rules and regulations of the Principal Market. 

Notwithstanding anything in this Warrant to the contrary, the Company shall be entitled to treat the registered Holder of this Warrant as
such appears in its records, as the owner of this Warrant for all purposes; provided, that such records are kept current using a reasonably satisfactory and customary method intended for such purpose. 
 2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted
from time to time as follows: 
 (a) Adjustment upon Subdivision or Combination of Common Stock. If the Company at any
time on or after the Closing Date subdivides (by any forward stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of
shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Closing Date combines (by any
reverse stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to
such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(a) shall become effective at the close of business on the date the subdivision or
combination becomes effective. 
 (b) De Minimis Adjustments. No adjustment in the Exercise Price shall be required
unless such adjustment would require an increase or decrease of at least $0.01 in such price; provided, however, that any adjustment which by reason of this Section 2(b) is not required to be made shall be carried forward and
taken into account in any subsequent adjustments under this

  

 5 

 
Section 2. All calculations under this Section 2 shall be made by the Company in good faith and shall be made to the nearest cent or to the nearest one hundredth of a share, as
applicable. No adjustment need be made for a change in the par value or no par value of the Company’s Common Stock. 
 3.
RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any dividend, other distribution of its assets (or rights to acquire its assets) or evidences of its indebtedness to holders of shares of Common Stock generally (which
dividend or other distribution has not already been given to the Holder with respect to the Warrant Shares), by way of return of capital or otherwise not addressed by Section 2 above (including, without limitation, any distribution of cash,
stock or other securities, property or options by way of a dividend, stock split, spin off, subdivision, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time
after the issuance of this Warrant and prior to the Expiration Date, then, in each such case: 
 (a) any Exercise Price in
effect immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date,
to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the Closing Bid Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the
Distribution (as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator shall be the Closing Bid Price of the shares of Common Stock on the Trading Day immediately
preceding such record date; and 
 (b) the number of Warrant Shares shall be increased or decreased to a number of shares equal
to the number of shares of Common Stock obtainable immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of
the fraction set forth in the immediately preceding paragraph (a); provided, that in the event that the Distribution is of shares of Common Stock or common stock of a company whose common shares are traded on a national securities exchange or
a national automated quotation system (“Other Shares of Common Stock”), then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an adjustment in the number of Warrant Shares, the terms of
which shall be identical to those of this Warrant, except that such warrant shall be exercisable into the number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution had the Holder
exercised this Warrant immediately prior to such record date and with an aggregate exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the terms of
the immediately preceding paragraph (a) and the number of Warrant Shares calculated in accordance with the first part of this paragraph (b). 
 4. FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is outstanding there is a Fundamental Transaction, then the Holder shall have the right thereafter to receive, upon exercise of this
Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the Holder of the
number of Warrant

  

 6 

 
Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration”). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a
Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Any successor to the Company or surviving entity in such
Fundamental Transaction shall issue to the Holder a new warrant substantially in the form of this Warrant and consistent with the foregoing provisions and evidencing the Holder’s right to purchase the Alternate Consideration for the aggregate
Exercise Price upon exercise thereof. 
 Notwithstanding the foregoing, at any time during the period beginning after the
Holder’s receipt of a notice from the Company of a Fundamental Transaction and ending five (5) days prior to the scheduled consummation of such Fundamental Transaction, the Holder may require the Company to redeem (a “Redemption
Upon Fundamental Transaction”) all or any portion of this Warrant not to be so assumed pursuant to the provisions of this Section 4 by delivering written notice thereof (“Fundamental Transaction Redemption Notice”) to
the Company, which Fundamental Transaction Redemption Notice shall indicate the portion of the remaining unexercised portion of this Warrant that the Holder is electing to have redeemed. The portion of this Warrant to be redeemed pursuant to this
Section 4 shall be redeemed by the Company at a price payable (x) in the case of a Cash-Out Fundamental Transaction or in the case of a Mixed Fundamental Transaction to the extent of the percentage of the cash consideration in such Mixed
Fundamental Transaction (determined in accordance with the definition of a Mixed Fundamental Transaction below), in cash equal to the Black Scholes Value of the redeemed portion of this Warrant, and (y) in the case of a Fundamental Transaction
not described in the foregoing subclause (x) or to the extent of the percentage of the consideration represented by securities of the successor entity in a Mixed Fundamental Transaction (as determined in accordance with the definition of Mixed
Fundamental Transaction below), in a number of shares of the Common Stock equal to the Black Scholes Value of the portion of this Warrant subject to redemption under this clause (y) divided by the Weighted Average Price of the Common Stock on
the principal securities exchange or other securities market on which the Common Stock is then being traded on the Trading Day immediately preceding the date on which the Fundamental Transaction is consummated. 
 The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or
surviving entity to comply with the provisions of this Section 4 and insuring that the provisions of this Warrant (or any such replacement security) shall similarly apply to subsequent transactions analogous to a Fundamental Transaction.

 5. CERTIFICATE OF ADJUSTMENT. Whenever the Exercise Price or number or type of securities issuable upon exercise of
this Warrant is adjusted, as herein provided, the Company shall, at its expense, promptly deliver to the Holder a certificate of an officer of the Company setting forth the nature of such adjustment and showing in detail the facts upon which such
adjustment is based. 
  

 7 

 6. COVENANT TO PERFORM. The Company hereby covenants and agrees that the Company will
at all times in good faith carry out all the provisions of this Warrant and take all action that is required hereunder to protect the rights of the Holder set forth in this Warrant. Without limiting the generality of the foregoing, the Company
(i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as this Warrant is outstanding, take action necessary to reserve and keep available out of its
authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of this Warrant, 100% of the number of shares of Common Stock issuable upon exercise of this Warrant then outstanding (without regard to any limitations
on exercise). 
 7. WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the
Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be
construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any
reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares
which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this
Warrant or otherwise) or as a stockholder of the Company. 
 8. REISSUANCE OF WARRANTS. 
 (a) Transfer of Warrant. Subject to compliance with applicable federal and state securities laws, this Warrant may be transferred by
the Holder with respect to any or all of the Warrant Shares purchasable hereunder. Upon surrender of this Warrant to the Company, together with the Notice of Assignment in the form attached hereto as Exhibit B duly completed and executed on
behalf of the Holder, for transfer of this Warrant as an entirety by the Holder, the Company shall issue a new Warrant of the same denomination to the assignee. Upon surrender of this Warrant to the Company, together with the Notice of Assignment in
the form attached hereto as Exhibit B duly completed and executed on behalf of the Holder, for transfer of this Warrant with respect to a portion of the Warrant Shares purchasable hereunder, the Company will forthwith issue and deliver upon
the order of the Holder a new Warrant (in accordance with Section 8(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of
Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 8(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. 
 (b) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the

  

 8 

 
Company reasonably satisfactory to the Company and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant
(in accordance with Section 8(d)) representing the right to purchase the Warrant Shares then underlying this Warrant. 
 (c) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 8(d)) representing
in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such
surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given. 
 (d)
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face
of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 8(a) or Section 8(c), the Warrant Shares designated by the Holder which, when
added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated
on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant. 
 9. RESERVATION OF STOCK. The Company covenants that during the period this Warrant is exercisable, the Company will reserve from its authorized and unissued Common Stock a sufficient number of
shares of Common Stock (or other securities, if applicable) to provide for the issuance of Warrant Shares (or other securities) upon the exercise of this Warrant. The Company agrees that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of this Warrant. 
 10. NOTICES OF RECORD DATE. In the event of: 
 (a) any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend
payable out of earned surplus of the Company) or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, or to receive any other right; or 
 (b) any Fundamental Transaction; or 
 (c) any voluntary or involuntary dissolution, liquidation or winding-up of the Company, 
 then and in each such event the Company will mail or cause to be delivered to the Holder (or a permitted transferee) a notice specifying (i) the date on which any such record is to be taken for the

  

 9 

 
purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, and (ii) the date on which any such Fundamental Transaction,
dissolution, liquidation or winding-up is to take place, and the time, if any, as of which the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or
other property deliverable upon such Fundamental Transaction, dissolution, liquidation or winding-up. Such notice shall be delivered at least ten (10) days prior to the date therein specified. 
 11. NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given
in accordance with Section 8.3 of the Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason
therefor. 
 12. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended
and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. 
 13. GOVERNING LAW. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the
construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of California, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
California or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of California. 
 14. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any person as the drafter hereof. The headings of
this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. 
 15.
DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price, the arithmetic calculation of the Warrant Shares or under Sections 2, 3 or 4, the disputing party shall submit the disputed determinations or
arithmetic calculations to the other party in accordance with Section 11. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3) Business Days
of such disputed determination or arithmetic calculation being submitted to the non-disputing party, then the Company shall, within two (2) Business Days submit the dispute to an independent, reputable accountant. The Company shall cause, at
the expense of the prevailing party, the accountant to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed determinations or
calculations. Such accountant’s determination or calculation shall be binding upon all parties absent demonstrable error. 
 16. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies

  

 10 

 
available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue
actual damages for any failure by the Company to comply with the terms of this Warrant. 
 17. TRANSFER OF WARRANT
SHARES. The holder of this Warrant acknowledges that the Warrant Shares have not been registered under the Securities Act or applicable state securities laws (collectively, the “Acts”), and agrees not to sell, encumber or
otherwise transfer any Warrant Shares issued upon its exercise unless (i) there is an effective registration statement under the Acts covering the transaction, (ii) the Company receives an opinion of counsel satisfactory to the Company
that such registration is not required under the Acts, or (iii) the Company otherwise satisfies itself that registration is not required under the Acts, it being understood that no such opinion of counsel shall be required in connection with
sales pursuant to Rule 144 under the Act. Each certificate or other instrument for Warrant Shares issued upon the exercise of this Warrant shall bear a legend substantially to the foregoing effect and as set forth in Section 4.12 of the
Purchase Agreement. 
 18. SATURDAYS, SUNDAYS, HOLIDAYS, ETC. If the last or appointed day for the taking of any action
or the expiration of any right required or granted herein shall be a Saturday or Sunday or shall be a legal U.S. holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday or legal U.S.
holiday. 
 19. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 (a) “Black Scholes Value” means the value of this Warrant based on the Black and Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg determined as of the day of the closing of the applicable Fundamental Transaction for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately
following the public announcement of the applicable Fundamental Transaction and (iii) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non cash
consideration, if any, being offered in the Fundamental Transaction, such non-cash values to be as set forth in any definitive agreement for the Fundamental Transaction that has been executed around the time of the first public announcement of the
Fundamental Transaction or, if no such value is determinable from such definitive agreement, based on the closing market price for shares of the successor entity on its principal securities exchange or quotation system on the Trading Day preceding
the first public announcement of the Fundamental Transaction or, if the successor entity is not a Publicly Traded Successor Entity, then as mutually determined in good faith by the Holder and the Company’s Board of Directors. In addition, for
purposes of determining the Black Scholes Value, this Warrant shall be deemed to be exercisable from and after the date of issuance of the Warrant regardless of any restrictions on exercisability. 
 (b) “Bloomberg” means Bloomberg Financial Markets. 
  

 11 

 (c) “Business Day” means any day other than Saturday, Sunday or other day
on which commercial banks in The City of New York or San Jose, California are authorized or required by law to remain closed. 
 (d) “Cash-Out Fundamental Transaction” means a Fundamental Transaction in which the consideration payable to holders of the Common Stock in connection with the Fundamental Transaction consists solely of cash. 
 (e) “Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing
bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the
closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities
exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or
if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or
last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC
(formerly the National Quotation Bureau, Inc.). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case
may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be
resolved pursuant to Section 15. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. 
 (f) “Common Stock” means (i) the Company’s shares of Common Stock, par value $0.001 per share, and (ii) any
share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock. 
 (g) “Expiration Date” means the date sixty-six (66) months after the Issuance Date or, if such date falls on a day other than a Business Day or on which trading does not take place
on the Principal Market (a “Holiday”), the next date that is not a Holiday. 
 (h) “Fundamental
Transaction” means that the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell,
assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or (iii) allow another Person to make a purchase, tender or exchange offer that is accepted by such number
of holders of outstanding shares of Common Stock resulting in such Person (together with any affiliates of such Person) holding more than 50% of the outstanding Common Stock of the Company following such purchase, tender or exchange offer, or
(iv) consummate a stock purchase

  

 12 

 
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person resulting in such other Person
(together with any affiliates of such Person) holding more than the 50% of the outstanding Common Stock of the Company following such stock purchase agreement or other business combination or (v) reorganize, recapitalize or reclassify its
Common Stock. 
 (i) “Mixed Fundamental Transaction” means a Fundamental Transaction where the consideration
payable to stockholders of the Company consists partially of cash and partially of securities of a successor entity. If the successor entity is a Publicly Traded Successor Entity, the percentage of consideration represented by securities of such
successor entity shall be equal to the quotient of (x) the product of the aggregate anticipated number of shares of the Publicly Traded Successor Entity to be issued (based on the Trading Day preceding the first public announcement of the Mixed
Fundamental Transaction) to holders of the Common Stock of the Company multiplied by the closing market price for such shares of the Publicly Traded Successor Entity on its principal securities exchange on the Trading Day preceding the first public
announcement of the Mixed Fundamental Transaction, divided by (y) the sum of the amount determined in subclause (x) plus the aggregate value of other consideration, including cash consideration, in such Fundamental Transaction. If the
successor entity is not a Publicly Traded Successor Entity, the percentage of consideration represented by securities of such successor entity shall be as mutually determined in good faith by the Holder and the Company’s Board of Directors.

 (j) “Person” means an individual, a limited liability company, a partnership, a joint venture, a
corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. 
 (k) “Principal Market” means The NASDAQ Global Market. 
 (l) “Publicly Traded Successor
Entity” means a successor entity that is a publicly traded corporation whose common stock is quoted on or listed for trading on the over the counter Bulletin Board, the New York Stock Exchange, Inc., the NYSE Arca, the NASDAQ Capital
Market, the NASDAQ Global Market, the NASDAQ Global Select Market or the NYSE Amex. 
 (m) “Trading Day” means
any day on which the Common Stock are traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock are
then traded; provided that “Trading Day” shall not include any day on which the Common Stock are scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock are suspended from trading during the
final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time). 
 (n) “Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average price for such
security on the Principal Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its “Volume at Price” function or, if the
foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the

  

 13 

 
electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg,
or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the
“pink sheets” by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price of such security
on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to
Section 15 with the term “Weighted Average Price” being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any share dividend, share split or other similar transaction
during such period. 
 [Signature Page Follows] 
  

 14 

 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to
be duly executed as of the Issuance Date set out above. 
  

			
	SOLTA MEDICAL, INC.
		
	By:	 	  

	Name:	 	Stephen J. Fanning
	Title:	 	Chairman, CEO & President

 EXHIBIT A 
 EXERCISE NOTICE 
 TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE
THIS 
 WARRANT TO PURCHASE COMMON STOCK 
 SOLTA MEDICAL, INC. 
 The undersigned holder hereby exercises the right to
purchase of the shares of Common Stock (“Warrant Shares”) of Solta Medical, Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant. 
 1.
Form of Exercise Price. The Holder’s payment of the Exercise Price shall be made as: 
  

			
	a “Cash Exercise” with respect to	  	Warrant Shares; and/or
		
	a “Cashless Exercise” with respect to	  	Warrant Shares.

 2. Payment of Exercise Price. In the event that the Holder conducted a Cash
Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $ to the Company in accordance with the terms of the Warrant. 
 3. Delivery of Warrant Shares. The Company shall deliver to the Holder Warrant Shares in accordance with the terms of the Warrant.

 4. Confirmation. Please send confirmation of receipt of this Exercise Notice to the following facsimile number:

  

			
	Date:                 ,
	
	  

		 	Name of Registered Holder
		
	By:	 	  

		 	Name:
		 	Title:

 ACKNOWLEDGMENT 
 The Company hereby acknowledges this Exercise Notice and hereby directs American Stock Transfer & Trust Company to issue the above
indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated from the Company and acknowledged and agreed to by American Stock Transfer & Trust Company. 
  

			
	SOLTA MEDICAL, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 EXHIBIT B 
 NOTICE OF ASSIGNMENT FORM 
 FOR VALUE RECEIVED,
                                         
    (the “Assignor”) hereby sells, assigns and transfers all of the rights of the undersigned Assignor under the attached Warrant with respect to the number of shares of common stock of Solta Medical, Inc. (the
“Company”) covered thereby set forth below, to the following “Assignee” and, in connection with such transfer, represents and warrants to the Company that the transfer is in compliance with the Warrant and
applicable federal and state securities laws: 
  

									
	NAME OF ASSIGNEE	 		 	ADDRESS/FAX NUMBER
					
	Dated:	 	  
	 		 	Signature:	 	  

					
		 		 		 	Witness:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]